Patents by Inventor Maria Paula CARRANZA SANDMEIER

Maria Paula CARRANZA SANDMEIER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240316172
    Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).
    Type: Application
    Filed: January 29, 2024
    Publication date: September 26, 2024
    Inventors: Jeroen GEURTSEN, Jan Theunis POOLMAN, Kellen Cristhina FAE, Pieter Jan BURGHOUT, Eveline Marleen WEERDENBURG, Patricia IBARRA YON, Darren Robert ABBANAT, Stefan Jochen KEMMLER, Michael Thomas KOWARIK, Manuela MALLY, Veronica GAMBILLARA FONCK, Martin Edward BRAUN, Maria Paula CARRANZA SANDMEIER
  • Patent number: 11931405
    Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).
    Type: Grant
    Filed: July 28, 2022
    Date of Patent: March 19, 2024
    Assignees: GlaxoSmithKline Biologicals S.A.
    Inventors: Jeroen Geurtsen, Jan Theunis Poolman, Kellen Cristhina Fae, Pieter Jan Burghout, Eveline Marleen Weerdenburg, Patricia Ibarra Yon, Darren Robert Abbanat, Stefan Jochen Kemmler, Michael Thomas Kowarik, Manuela Mally, Veronica Gambillara Fonck, Martin Edward Braun, Maria Paula Carranza Sandmeier
  • Publication number: 20230293657
    Abstract: The present invention relates to the field of immunogenic compositions and vaccines, their manufacture, host cells which can be used in their manufacture and the use of such immunogenic compositions and vaccines in medicine. More particularly, it relates to Klebsiella pneumoniae O-antigens, conjugates comprising a K. pneumoniae O-antigen, host cells suitable for their production and immunogenic compositions or vaccines containing at least one Klebsiella pneumoniae O-antigen.
    Type: Application
    Filed: June 17, 2021
    Publication date: September 21, 2023
    Inventors: Maria Paula CARRANZA SANDMEIER, Rainer FOLLADOR, Veronica Gambillara FONCK, Stefan Jochen KEMMLER, Patricia Martin KILLIAS, Michael Thomas KOWARIK, Gerd Martin LIPOWSKY, Gerald Johann POSCH, Fabio SERVENTI, Dominique Nicolas SIRENA
  • Publication number: 20230190926
    Abstract: Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).
    Type: Application
    Filed: October 6, 2022
    Publication date: June 22, 2023
    Inventors: Jeroen GEURTSEN, Pieter Jan BURGHOUT, Eveline Marleen WEERDENBURG, Jan Theunis POOLMAN, Kellen Cristhina FAE, Patricia IBARRA YON, Darren Robert ABBANAT, Stefan Jochen KEMMLER, Michael Thomas KOWARIK, Manuela MALLY, Veronica GAMBILLARA FONCK, Martin Edward BRAUN, Maria Paula CARRANZA SANDMEIER
  • Publication number: 20230118878
    Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).
    Type: Application
    Filed: July 28, 2022
    Publication date: April 20, 2023
    Inventors: Jeroen GEURTSEN, Jan Theunis POOLMAN, Kellen Cristhina FAE, Pieter Jan BURGHOUT, Eveline Marleen WEERDENBURG, Patricia IBARRA YON, Darren Robert ABBANAT, Stefan Jochen KEMMLER, Michael Thomas KOWARIK, Manuela MALLY, Veronica GAMBILLARA FONCK, Martin Edward BRAUN, Maria Paula CARRANZA SANDMEIER
  • Patent number: 11491220
    Abstract: Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: November 8, 2022
    Assignees: Janssen Pharmaceuticals, Inc.
    Inventors: Jeroen Geurtsen, Pieter Jan Burghout, Eveline Marleen Weerdenburg, Jan Theunis Poolman, Kellen Cristhina Fae, Patricia Ibarra Yon, Darren Robert Abbanat, Stefan Jochen Kemmler, Michael Thomas Kowarik, Manuela Mally, Veronica Gambillara Fonck, Martin Edward Braun, Maria Paula Carranza Sandmeier
  • Patent number: 11446370
    Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: September 20, 2022
    Assignees: Janssen Pharmaceuticals, Inc., GlaxoSmithKline Biologicals S.A.
    Inventors: Jeroen Geurtsen, Jan Theunis Poolman, Kellen Cristhina Fae, Pieter Jan Burghout, Eveline Marleen Weerdenburg, Patricia Ibarra Yon, Darren Robert Abbanat, Stefan Jochen Kemmler, Michael Thomas Kowarik, Manuela Mally, Veronica Gambillara Fonck, Martin Edward Braun, Maria Paula Carranza Sandmeier
  • Publication number: 20200353073
    Abstract: Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).
    Type: Application
    Filed: March 18, 2020
    Publication date: November 12, 2020
    Inventors: Jeroen GEURTSEN, Pieter Jan BURGHOUT, Eveline Marleen WEERDENBURG, Jan Theunis POOLMAN, Kellen Cristhina FAE, Patricia IBARRA YON, Darren Robert ABBANAT, Stefan Jochen KEMMLER, Michael Thomas KOWARIK, Manuela MALLY, Veronica GAMBILLARA FONCK, Martin Edward BRAUN, Maria Paula CARRANZA SANDMEIER
  • Publication number: 20200316184
    Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).
    Type: Application
    Filed: March 18, 2020
    Publication date: October 8, 2020
    Inventors: Jeroen GEURTSEN, Jan Theunis POOLMAN, Kellen Cristhina FAE, Pieter Jan BURGHOUT, Eveline Marleen WEERDENBURG, Patricia IBARRA YON, Darren Robert ABBANAT, Stefan Jochen KEMMLER, Michael Thomas KOWARIK, Manuela MALLY, Veronica GAMBILLARA FONCK, Martin Edward BRAUN, Maria Paula CARRANZA SANDMEIER